RE:Next batch of CR% results????
wildbird1 wrote: We don't know what the next batch of CR%(Complete Response) will be.
But we know this...
In the June 24,2022 PressRelease, Dr. Arkady Mandel said" The success in the Phase 1b NMIBC clinical study has led to the impressive preliminary results demonstrated in the Phase 11 NMIBC clinical study, focused primarily on efficacy and secondary on safety. In the future, I foresee great potential for Theralase Anti-cancer therapy (ACT) to deliver a safe and effective anti-cancer treatment for numerous cancer indications with high unmet needs".
Everyday we are getting closer & closer to these impressive results that will get TLT BTD(Break Through Designation).
Note1) Dr.Mandel is a scientist (Chief Scientific Officer of TLT), scientists have a tendency to be careful and more concervative when making predictions.
Note 2) Big Pharma are going to love "Numerous cancer indications with unmet needs"
Be ready for it, in the near future, events could unfold rapidly.
....& perhaps boost treatment responses for those indications that already have partially met needs. Could Ru(II) complexes (&/or its derivatives) augment or even replace the traditionally used platinum-based drugs & even other chemotherapies (I.e. Anthracyclines like Doxorubicin)? Platinum-based therapies alone have been reported to be used in the treatment of ~50-70% of cancers. There could be more to this picture than meets the eye....all imo. Good luck...
Lin K, Rong Y, Chen D, Zhao Z, Bo H, Qiao A, Hao X, Wang J. Combination of Ruthenium Complex and Doxorubicin Synergistically Inhibits Cancer Cell Growth by Down-Regulating PI3K/AKT Signaling Pathway. Front Oncol. 2020 Feb 18;10:141. doi: 10.3389/fonc.2020.00141. PMID: 32133289; PMCID: PMC7041628.
Abstract
Combinational use of drugs has been a common strategy in cancer treatment because of synergistic advantages in reducing dose and toxicity, minimizing or delaying drug resistance. To improve the efficacy of chemotherapy, various potential combinations have been investigated. Ruthenium complex is considered a potential alternative of the platinum-based drugs due to its significant efficacy and safety. Previously, we reported that ruthenium(II) complex (Δ-Ru1) has great anticancer potential and minor toxicity toward normal tissues. However, the therapeutic efficacy and mechanism of action of ruthenium(II) complex combined with other anticancer drugs is still unknown. Here, we investigated the combinational effect of Δ-Ru1 and doxorubicin in different cancer cells. The data assessed by Chou-Talalay method showed significant synergism in MCF-7 cells. Furthermore, the results in antiproliferation efficacy indicated that the combination showed strong cytotoxicity and increasing apoptosis of MCF-7 cells in 2D and 3D multicellular tumor spheroids (MCTSs). Significant inhibition of MCF-7 cells accompanied with increased ROS generation was observed. Furthermore, the expression of PI3K/AKT was significantly down-regulated, while the expression of PTEN was strongly up-regulated in cells treated with combination of Δ-Ru1 and doxorubicin. The expression of NF-κB and XIAP decreased while the expression of P53 increased and associated with apoptosis. These findings suggest that the combination of ruthenium complex and doxorubicin has a significant synergistic effect by down-regulating the PI3K/AKT signaling pathway in MCF-7 cells. This study may trigger more research in ruthenium complex and combination therapy that will be able to provide opportunities for developing better therapeutics for cancer treatment.